Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07305259 · ClinicalTrials.gov registry record · Early Phase 1
Researching Economical Adjuvants to Cancer Therapy
A Early Phase 1 study of Healthy Participants, sponsored by Florida State University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07305259 is a Early Phase 1 study of Healthy Participants that is actively recruiting participants, run by Florida State University. The registered enrollment target is 60 participants, roughly in line with the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT07305259, a Early Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Florida State University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if beta-glucan (a dietary fiber) improves the function of the immune system in adults. It will also tell the investigators if combining beta-glucan with single bouts of exercise provides additional benefit. The main questions it aims to answer are: 1. Does beta-glucan change the ability of immune cells to recognize cancer cells? 2. Does exercise change the type of immune cells in the blood? Researchers will compare beta-glucan to a placebo (a look-alike substance with no effect) to see if beta-glucan could improve immune function against cancer. Participants will: 1. Take beta-glucan or a placebo daily for 4 weeks. 2. Visit the laboratory for three exercise tests. 3. Provide blood samples so researchers can study immune system cells.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Beta-glucan
Study Locations (1)
Florida
- Institute of Sports Sciences and Medicine - Tallahassee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2029-09-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07305259
The ClinicalTrials.gov registry entry for NCT07305259 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target. The listed sponsor is Florida State University, which has 219 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07305259 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07305259 about?
NCT07305259 is a clinical study titled "Researching Economical Adjuvants to Cancer Therapy". The goal of this clinical trial is to learn if beta-glucan (a dietary fiber) improves the function of the immune system in adults. It will also tell the investigators if combining beta-glucan with single bouts of exercise provides additional benefit. The main questions it aims to answer are: 1. Doe...
What is the current status of trial NCT07305259?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2025-11-12. Estimated completion is 2029-09-30.
What conditions does trial NCT07305259 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07305259?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Beta-glucan (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07305259?
This trial is sponsored by Florida State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07305259 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
RECRUITING · Early Phase 1
-
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
RECRUITING · Early Phase 1
-
Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration
COMPLETED · Early Phase 1
-
Washington University WU 409: Immune Responses to Rabies Vaccine.
COMPLETED · Early Phase 1
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.